Related Experiment Video
Updated: Dec 12, 2025

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
Published on: June 3, 2018
MicroRNA-144 regulates angiotensin II-induced cardiac fibroblast activation by targeting CREB
Zhi-Yong Liu1, Mingjun Lu2, Jing Liu3
1Department of Cardiology, Dezhou People's Hospital, Dezhou, Shandong 253014, P.R. China.
Abstract:
Cardiac fibrosis is involved in adverse cardiac remodeling and heart failure, which is the leading cause of deteriorated cardiac function. Accumulative evidence has elucidated that microRNAs (miRNAs) play important roles in the pathogenesis of cardiac fibrosis. However, the exact molecular mechanism underlying miR-144 in cardiac fibrosis remains unknown. In the present study, a transverse aortic constriction (TAC) mouse model and angiotensin II (Ang II)-induced cardiac fibroblasts (CFs) were constructed in order to investigate the expression levels of miR-144. It was demonstrated that miR-144 was significantly downregulated following pathological stimuli. CFs infected with miR-144 mimics were then used to test the effect of miR-144 on CF activation in vitro. The results revealed that overexpression of miR-144 led to a dramatically decreased proliferation and migration ability in CFs, as well as the transformation from fibroblasts to myofibroblasts, which was characterized by the decreased expression of collagen-I, collagen-III, CTGF, fibronectin and α-SMA. By contrast, such effects could be reversed by miR-144 knockdown. Mechanistically, the bioinformatics analysis and luciferase reporter assay in the present study demonstrated that cAMP response element-binding protein (CREB) was a direct target of miR-144, and the expression of CREB was attenuated by miR-144. The results of the present study demonstrated that miR-144 played a key role in CF activation, partially by targeting CREB, which further suggested that the overexpression of miR-144 may be a promising strategy for the treatment of cardiac fibrosis.
Insights
MicroRNA-144 (miR-144) is downregulated in cardiac fibrosis. Overexpressing miR-144 inhibits fibroblast activation and collagen production, suggesting it as a potential therapeutic target for heart failure.
Area of Science:
- Cardiovascular Biology
- Molecular Medicine
- Fibrosis Research
Background:
- Cardiac fibrosis contributes to heart failure and impaired cardiac function.
- MicroRNAs (miRNAs) are implicated in cardiac fibrosis pathogenesis.
- The specific role of miR-144 in cardiac fibrosis requires elucidation.
Purpose of the Study:
- To investigate the role and mechanism of miR-144 in cardiac fibrosis.
- To determine miR-144 expression levels in response to pathological stimuli.
- To explore miR-144's effect on cardiac fibroblast activation and its therapeutic potential.
Main Methods:
- Utilized a transverse aortic constriction (TAC) mouse model and angiotensin II (Ang II)-induced cardiac fibroblasts (CFs).
- Assessed miR-144 expression levels.
- Employed miR-144 mimics and knockdown in vitro to study effects on CF proliferation, migration, and myofibroblast transformation.
- Conducted bioinformatics analysis and luciferase reporter assays to identify miR-144 targets.
Main Results:
- miR-144 expression was significantly downregulated under pathological conditions.
- Overexpression of miR-144 reduced CF proliferation, migration, and myofibroblast differentiation, decreasing collagen I, collagen III, CTGF, fibronectin, and α-SMA expression.
- miR-144 directly targeted cAMP response element-binding protein (CREB), attenuating its expression.
- miR-144 knockdown reversed these antifibrotic effects.
Conclusions:
- miR-144 plays a crucial role in regulating cardiac fibroblast activation.
- The antifibrotic effects of miR-144 are partly mediated through targeting CREB.
- Overexpression of miR-144 presents a promising therapeutic strategy for treating cardiac fibrosis.
Related Concept Videos
Master Transcription Regulators
MAPK Signaling Cascades
Regulation of Angiogenesis and Blood Supply
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
TGF - β Signaling Pathway
MicroRNAs

